Jump to content

Derrick Rossi

From Wikipedia, the free encyclopedia
Derrick Rossi, 2008

Derrick J. Rossi (born 5 February 1966),[1] is a Canadian stem cell biologist and entrepreneur. He is a co-founder of the pharmaceutical company Moderna.

Early life and education[edit]

Rossi was born in Toronto as the youngest of five children of a Maltese immigrant family.[2] His father Fred worked in auto body shops for 50 years[3] and his mother Agnes co-owned a Maltese bakery.[2]

Rossi attended the Dr. Norman Bethune High School in Scarborough where he early discovered his passion for molecular biology.[2] He then did his undergraduate and master's degrees in molecular genetics at the University of Toronto.[4] He earned his Ph.D. from the University of Helsinki in 2003 and held a post-doc position from 2003 to 2007 at Stanford University in Irving Weissman’s lab.[5]

Career[edit]

Rossi was appointed Associate Professor at the Stem Cell and Regenerative Biology Department at Harvard Medical School and Harvard University.[when?][6] At the same time he was a principal faculty member of the Harvard Stem Cell Institute and an investigator at the Immune Disease Institute (IDI),[7] as well as in the Program in Cellular and Molecular Medicine at the Children’s Hospital Boston.[8]

Moderna was founded in 2010, based on discovery that pluripotent stem cells can be transformed and reprogrammed.[9][10] Time magazine cited this pluripotent discovery as one of the top ten medical breakthroughs of the year.[11]

In 2013 Rossi, Chien and their team reported that they "were able to improve heart function in mice and enhance their long-term survival with a "redirection of their [stem cell] differentiation toward cardiovascular cell types" in a significant step towards regenerative therapeutics for Moderna.[12][13] In the same year and on the strength of the same paper Moderna was able to partner with AstraZeneca in exchange for $240 million "in upfront cash (plus much more in potential milestone payments)", and then received from other investors $110 million.[12]

In 2014 Rossi retired from his functions at the board and as a scientific advisor at Moderna.[2]

In 2015 Rossi was scientific co-founder of Intellia Therapeutics. In 2016 Rossi co-founded Magenta Therapeutics. Rossi was involved in the foundation of Stelexis Therapeutics, which develops new medication for treating cancerous stem cells.[when?][6][4][14]

In 2018 Rossi retired from all of his Harvard positions in order to focus on his activities as an entrepreneur.[4][2] Rossi serves as the interim CEO of the New York Stem Cell Foundation.[6] Rossi is also CEO of Convelo Therapeutics.[15]

Scientific contributions[edit]

Rossi develops and promotes new therapies using biotechnological methods thus contributing to novel approaches in regenerative medicine.[6] His research focussed on different aspects of stem cell biology.[4] In order to avoid ethical issues related to the use and exploitation of human stem cells, Rossi based his developments on the results of Katalin Karikó and Drew Weissman on mRNA. He succeeded in finding investors for his plans to transfer these findings into new medications and vaccinations by founding Moderna.[16]

Rossi is on record as writing of his synthetic modified mRNA: "because our technology is RNA based, it completely eliminates the risk of genomic integration and insertional mutagenesis inherent to all DNA-based methodologies."[17]

Awards and honours[edit]

In 2021 he was awarded the Princess of Asturias Award in the category "Scientific Research".[18]

Selected papers[edit]

  • Derrick J Rossi; David Bryder; Jun Seita; Andre Nussenzweig; Jan Hoeijmakers; Irving L Weissman (1 June 2007). "Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age". Nature. 447 (7145): 725–729. doi:10.1038/NATURE05862. ISSN 1476-4687. PMID 17554309. Wikidata Q28505636.
  • Luigi Warren; Philip D Manos; Tim Ahfeldt; et al. (30 September 2010). "Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA". Cell Stem Cell. 7 (5): 618–630. doi:10.1016/J.STEM.2010.08.012. ISSN 1934-5909. PMC 3656821. PMID 20888316. Wikidata Q28131663.
  • Athurva Gore; Zhe Li; Ho-Lim Fung; et al. (1 March 2011). "Somatic coding mutations in human induced pluripotent stem cells". Nature. 471 (7336): 63–67. doi:10.1038/NATURE09805. ISSN 1476-4687. PMC 3074107. PMID 21368825. Wikidata Q29616798.

Family life[edit]

Rossi is married to Finnish biologist Nina Korsisaari and father of three daughters.[2][19]

References[edit]

  1. ^ American Men & Women of Science (2015). 33rd Edition. Cengage Learning: Detroit.
  2. ^ Jump up to: a b c d e f Joe O'Connor (28 May 2020). "Meet the Canadian hockey dad behind COVID-19 vaccine developer Moderna". nationalpost.com. Retrieved 6 March 2021.
  3. ^ "How Dad Made a Difference". The Orlando Sentinel. 16 June 2011. p. D1. Retrieved 9 August 2018.
  4. ^ Jump up to: a b c d Rahul Kalvapalle (22 February 2021). "From the lab to saving lives: Moderna co-founder Derrick Rossi on becoming a serial entrepreneur". utoronto.ca. Retrieved 6 March 2021.
  5. ^ "About the researcher". harvard.edu. Archived from the original on 9 February 2022. Retrieved 6 March 2021.
  6. ^ Jump up to: a b c d "Derrick Rossi, PhD". NYSCF. Retrieved 6 March 2021.
  7. ^ "Derrick J Rossi's scientific contributionswhile affiliated with Harvard University (Cambridge, United States) and other places". Research Gate. Retrieved 26 February 2018.
  8. ^ "Derrick J. Rossi, Ph.D." VOR Biopharma. Archived from the original on 26 February 2018. Retrieved 26 February 2018.
  9. ^ Kutz, Erin (4 October 2010). "ModeRNA, Stealth Startup Backed By Flagship, Unveils New Way to Make Stem Cells". Xconomy, Inc.
  10. ^ Lawrence Goodman (10 February 2021). "Rosenstiel Award winners celebrated for life-saving scientific breakthroughs". brandeis.edu. Retrieved 6 March 2021.
  11. ^ "Children's researcher honored by TIME Magazine". Thriving. Archived from the original on 26 February 2018. Retrieved 26 February 2018.
  12. ^ Jump up to: a b Timmerman, Luke (20 November 2013). "Moderna Vacuums Up Another $110M to Make Messenger RNA Drugs". Xconomy, Inc.
  13. ^ Lior Zangi; Kathy O Lui; Alexander von Gise; et al. (8 September 2013). "Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction". Nature Biotechnology. 31 (10): 898–907. doi:10.1038/NBT.2682. ISSN 1087-0156. PMC 4058317. PMID 24013197. Wikidata Q30580723.
  14. ^ Servick, Kelly (1 February 2017). "This mysterious $2 billion biotech is revealing the secrets behind its new drugs and vaccines". Science. Retrieved 9 August 2018.
  15. ^ "The Science of Startups: Drs. Derrick Rossi and Paul Tesar Discuss How Their Biotechs Are Bringing Stem Cell Research to Patients". Retrieved Dec 10, 2020.
  16. ^ Damian Garde, Jonathan Saltzman (10 November 2020). "The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race". statnews.com. Retrieved 6 March 2021.
  17. ^ Luigi Warren; Philip D Manos; Tim Ahfeldt; et al. (30 September 2010). "Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA". Cell Stem Cell. 7 (5): 618–630. doi:10.1016/J.STEM.2010.08.012. ISSN 1934-5909. PMC 3656821. PMID 20888316. Wikidata Q28131663.
  18. ^ IT, Developed with webControl CMS by Intermark. "Katalin Karikó, Drew Weissman, Philip Felgner, Uğur Şahin, Özlem Türeci, Derrick Rossi and Sarah Gilbert - Laureates - Princess of Asturias Awards". The Princess of Asturias Foundation. Retrieved 13 December 2021.
  19. ^ Courtney Shea (17 February 2020). ""It's likely we'll see another pandemic in the next 20 years": The Toronto scientist who invented the Covid vaccine technology says we need to prepare for the next virus". torontolife.com. Retrieved 6 March 2021.

External links[edit]

Scholia has a profile for Derrick Rossi (Q50173077).
Retrieved from "https://en.wikipedia.org/w/index.php?title=Derrick_Rossi&oldid=1218748837"